Clinical Trials
Multiple clinical trials evaluate metabolic, neurological, hepatic, and gastrointestinal conditions, including amyotrophic lateral sclerosis, chronic hepatitis B, cystic fibrosis, and short bowel syndrome. Spanning Phase 1 through Phase 4 with recruitment statuses ranging from active and completed to not yet recruiting, these studies focus on immune function and metabolic intervention. Sponsoring entities include academic medical centers and health organizations such as Emory University, University Hospital Geneva, and the National Institute of Allergy and Infectious Diseases.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05105958 | Not yet recruiting | Amyotrophic Lateral Sclerosis |
University Hospital Geneva|University of Lausanne Hospitals|University of Zurich|University of Bern|Cantonal Hospital of St. Gallen |
2025-12-01 | Phase 2 |
| NCT05847179 | Not yet recruiting | Werner Syndrome |
PRG Science & Technology Co. Ltd. |
2025-01-01 | Phase 2 |
| NCT06405555 | Not yet recruiting | Heart Failure With Reduced Ejection Fraction|Hypotension|LV Dysfunction |
Ottawa Heart Institute Research Corporation |
2024-08-01 | Phase 2|Phase 3 |
| NCT05706116 | Not yet recruiting | Whipworm|Trichuriasis|Controlled Human Infection |
George Washington University|National Institute of Allergy and Infectious Diseases (NIAID) |
2024-07-01 | Phase 1 |
| NCT04231565 | RECRUITING | Hepatitis B Virus |
Third Affiliated Hospital, Sun Yat-Sen University |
2020-06-04 | |
| NCT05797714 | ACTIVE_NOT_RECRUITING | HBV Infection; Chronic Hepatitis b |
Ruijin Hospital |
2022-06-08 | |
| NCT04022434 | UNKNOWN | Fructose Intolerance |
Augusta University |
2014-01-07 | |
| NCT03341169 | UNKNOWN | Aortic Valve Stenois |
Yonsei University |
2018-03-20 | |
| NCT02770417 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Hasselt University |
2016-05 | |
| NCT01576003 | COMPLETED | Bloodstream Infections; Short Bowel Syndrome; Development; Nutrition; Biological Markers |
Children's Hospital Medical Center, Cincinnati |
2012-04 | |
| NCT01944059 | TERMINATED | Migraine Headaches |
Vincent Martin, MD |
2013-11 | PHASE4 |
| NCT01833611 | UNKNOWN | Chronic Hepatitis |
National Cheng-Kung University Hospital |
2008-09 | PHASE4 |
| NCT00628381 | UNKNOWN | Sepsis; Multiple Organ Failure |
Maastricht University Medical Center |
2011-01 | PHASE3 |
| NCT01478126 | COMPLETED | Coronary Artery Disease |
Meshalkin Research Institute of Pathology of Circulation |
2012-01 | PHASE3 |
| NCT01288495 | TERMINATED | Dietary Fructose Intolerance |
Augusta University |
2009-02 | |
| NCT01051999 | COMPLETED | Cystic Fibrosis; Immune Function |
Emory University |
2010-02 | PHASE2 |
| NCT00575627 | UNKNOWN | Chronic Hepatitis C |
University of Turin, Italy |
2007-09 | PHASE4 |
| NCT00586885 | COMPLETED | Nonalcoholic Steatohepatitis |
Keith D Lindor, M.D. |
2004-02 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).